JJN-3

302882

GENERAL INFORMATION

Description

JJN-3 □□ □□ □□□□□□□□□□□□□ □□□□ 57 □□ □□ □□□ □□ JJN-3 □□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□ NRAS p.Gln61Lys □□ RAS □□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□ □□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□ □□□□□□□□□□□□□□□□□□□□□□□ CD38 □□□ CD138 □□□□□□□□□□□□□□□□ □□□

JJN-3 □□□, □□□□□□ □□□□□□□□□□□□□□□□□ NRAS Q61K, □□□ □□□□□□□□□□□□□ (bortezomib, lenalidomide, daratumumab, elotuzumab), □□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□ □□□ □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□ □□□ CD38, □□□□□□ IMiD, □□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□ RAS

Tissue	□□□□□□□□□
Disease	□□
Metastatic site	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (□□□□□□□□□□)

Applications

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□ NRAS Q61K; □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ (bortezomib, lenalidomide, daratumumab); □□□□□□□□□□□□□□□□□□□□□□□□□□□□ CD38; □□□□□□ IMiD; □□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□; □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Synonyms

- JJN3

CLASSIFICATION

Organism	Human
Sex	Female
Growth properties	Suspension
Biosafety level	1

CHARACTERISTICS

Morphology	□□□□□□□□□□□□□□□□□□□□□□□□□□□
Cell type	□□□□□□□□□□□□□
Doubling time	24 □□□□□□□□ ; ~20-35 □□□□□□□□

IDENTIFIERS

Citation

JJN-3 (□□□□□□□□□□□□□□□□□□□ Cytion 302882)

NCBI TaxID	9606
Cellosaurus	CVCL_2078

EXPRESSION AND SUSCEPTIBILITY

Mutational profile

□□□□□□□□□□□□□□□: p.Gln61Lys, □□□□□□□□□□□□□□□□□

HANDLING AND CULTURE

Culture medium

40% DMEM + 40% Iscove's MDM + 20% h.i. FBS

Supplements

□□□□□ FBS □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ 20% □□□□□□□□□□□□□□□□□□□□ (□□□□□□□□□□□□□□□□□□□□□□□□ AT □□□□□: DMEM 40% + IMDM 40% + FBS □□ 20%)

Dissociation reagent	□□□□□□□□□□□□ (□□□□□□□□□□□□□□□□□□□□□□□□)

Subculturing

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ 2–5 × 10^5 □□□□□□/□□□□□□□□□□ □□□ □□□□□□□□□□□ 2–3 □□□ □□□

Split ratio	1 □□□ 4
Seeding density	2 □□□ 5 × 10^5 □□□□□□/□□.
Fluid renewal	□□□ 2 □□□ 3 □□□

Thawing and culturing

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.
Follow the procedure described under Post-Thaw Recovery

QUALITY CONTROL AND CRYOPRESERVATION

Freeze medium	□□□ □□□□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ + 10% DMSO □□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Storage conditions

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□ −150 □□□ −196 °C □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ −80 °C □□ □□□□□□□□□□□□□□□□□□□□□□□□□□

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

Shipping conditions

[illegible] [illegible] −78 °C [illegible] [illegible] [illegible]

DONOR

Donor age	57 [illegible]
Ethnicity	[illegible]

LEGAL AND SAFETY

Safety precautions

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

Warranty

[illegible]Cytion [illegible]
[illegible]
60 [illegible]
[illegible]
[illegible] [illegible]/[illegible]
[illegible] [illegible]
<a href=""/Who-we-are/Warranty/"" hreflang=""x-default"">[illegible].

Material Transfer Agreement required	Yes